Management of Hyperuricemia

Initial Assessment

The European League Against Rheumatism recommends evaluating patients with hyperuricemia for specific risk factors, including previous gout attacks, radiographic signs, and clinical phase (acute/recurrent gout, intercritical gout, or chronic tophaceous gout) 2
The American College of Rheumatology suggests considering causes of hyperuricemia by checking for comorbidities such as obesity, hypertension, hyperlipidemia, diabetes, and kidney disease 3
The European League Against Rheumatism recommends screening for medications that may elevate uric acid levels, particularly thiazide and loop diuretics, niacin, and calcineurin inhibitors 3
For patients with early onset hyperuricemia (before age 25) or history of urolithiasis, the American College of Rheumatology recommends screening for uric acid overproduction through urine uric acid evaluation 3

The American College of Cardiology recommends providing patient education about the disease, treatment objectives, and lifestyle modifications 1
The European League Against Rheumatism suggests recommending weight loss if the patient is overweight or obese 1, 2
The American Heart Association advises reduction in alcohol consumption, especially beer and spirits 1
The Academy of Nutrition and Dietetics recommends avoiding sugar-sweetened drinks and foods rich in fructose 1
The American College of Rheumatology suggests limiting intake of purine-rich foods (red meat, seafood) 1
The National Dairy Council recommends encouraging consumption of low-fat dairy products 1
The American College of Sports Medicine advises regular physical activity 1

The European League Against Rheumatism recommends allopurinol as first-line therapy in patients with normal kidney function 1
The American College of Rheumatology suggests starting allopurinol at a low dose (100 mg/day) and increasing by 100 mg increments every 2-4 weeks until target serum uric acid level is reached 1
The European League Against Rheumatism recommends maintaining serum uric acid level <6 mg/dL (360 μmol/L) lifelong 1
For patients with renal impairment, the American College of Rheumatology suggests adjusting maximum dosage according to creatinine clearance 1
The European League Against Rheumatism recommends switching to febuxostat if target serum uric acid level cannot be reached with allopurinol or if allopurinol is not tolerated 1
The American College of Rheumatology suggests considering a uricosuric agent (e.g., probenecid) if target serum uric acid level cannot be reached with allopurinol or febuxostat 1

The European League Against Rheumatism recommends considering substituting the diuretic if possible when hyperuricemia occurs in patients receiving diuretics 1
The American Heart Association suggests considering losartan or calcium channel blockers for hypertension management in patients with hyperuricemia 1
The American College of Cardiology recommends considering statins or fenofibrate for hyperlipidemia management 1

The European League Against Rheumatism recommends monitoring serum uric acid levels regularly to ensure target level is maintained 1
The American College of Rheumatology suggests continuing ULT indefinitely to prevent recurrence once target serum uric acid level is achieved 1

The European League Against Rheumatism recommends avoiding targeting serum uric acid levels <3 mg/dL for long-term therapy 1
The American College of Rheumatology suggests considering referral to a specialist for unclear etiology of hyperuricemia, refractory symptoms, difficulty reaching target serum urate level, or multiple/serious adverse events from ULT 3